Awasthi, A., Rolland, D., Ayello, J., van de Ven, C., , Conlon, K., … Cairo, M. (2017). A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget, 8(69), 113895-113909. https://doi.org/10.18632/oncotarget.23040 (Original work published 2017)